

Performance (consolidated)

(¥ million)

	2015	2016	2017	2018	2019	2020	2021 (estimated)
Net Sales	84,209	98,781	101,448	114,716	116,637	121,885	135,000
Operating profit	8,549	15,280	17,079	20,644	21,668	26,134	28,000
Ordinary Profit	8,952	16,244	17,451	21,540	22,442	26,760	28,500
Profit attributable to owners of parent	6,340	11,749	12,953	16,302	16,866	20,702	21,000

Feb 10, 2022

(¥ million)

Brand name	Active Ingredient	Indications	Launch Date	Sales 2019	Sales 2020	Sales 2021	
						Apr.-Dec.	Annual (estimated)
Vidaza	azacitidine	myelodysplastic syndrome/ acute myeloid leukemia	Mar-2011/ Mar-2021	15,652	15,350	14,195	18,000
Upravi	selexipag	pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension	Nov-2016/ Aug-2021	6,182	6,804	6,160	8,600
Viltepso	viltolarsen	Duchenne muscular dystrophy	Japan May-2020 U.S. Aug-2020	-	2,387	5,476	8,800
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-2010	7,153	6,906	5,297	6,100
Gazyva	obinutuzumab	CD20-positive follicular lymphoma	Aug-2018	4,527	5,312	4,162	5,500
Adcirca	tadalafil	pulmonary arterial hypertension	Dec-2009	5,405	5,474	3,760	4,800
Zalutia	tadalafil	urinary disorder caused by benign prostatic hyperplasia	Apr-2014	13,328	6,743	3,316	3,900
Cialis	tadalafil	erectile dysfunction	Jul-2009	4,472	2,677	1,961	2,500
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-2019	1,071	1,970	1,586	2,100
Erizas	dexamethasone cipeclate	allergic rhinitis	Dec-2009	2,387	2,444	1,148	2,500
Profit in co-promotion				5,963	8,442	6,791	9,000
Revenues from the licensing of industrial property rights				15,860	24,338	26,814	32,000
Pharmaceuticals				101,643	106,478	93,625	119,300
Functional Food				14,994	15,406	12,593	15,700
Net Sales				116,637	121,885	106,218	135,000